[go: up one dir, main page]

IL160001A0 - Peptide based multimeric targeted contrast agents and methods for the preparation thereof - Google Patents

Peptide based multimeric targeted contrast agents and methods for the preparation thereof

Info

Publication number
IL160001A0
IL160001A0 IL16000102A IL16000102A IL160001A0 IL 160001 A0 IL160001 A0 IL 160001A0 IL 16000102 A IL16000102 A IL 16000102A IL 16000102 A IL16000102 A IL 16000102A IL 160001 A0 IL160001 A0 IL 160001A0
Authority
IL
Israel
Prior art keywords
preparation
methods
contrast agents
peptide based
targeted contrast
Prior art date
Application number
IL16000102A
Other languages
English (en)
Original Assignee
Epix Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epix Medical Inc filed Critical Epix Medical Inc
Publication of IL160001A0 publication Critical patent/IL160001A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0039—Coumarin dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/122—Macromolecular compounds dimers of complexes or complex-forming compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL16000102A 2001-07-30 2002-07-30 Peptide based multimeric targeted contrast agents and methods for the preparation thereof IL160001A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30872101P 2001-07-30 2001-07-30
PCT/US2002/024261 WO2003011115A2 (fr) 2001-07-30 2002-07-30 Agents de contraste multimères ciblés à base de peptides

Publications (1)

Publication Number Publication Date
IL160001A0 true IL160001A0 (en) 2004-06-20

Family

ID=23195121

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16000102A IL160001A0 (en) 2001-07-30 2002-07-30 Peptide based multimeric targeted contrast agents and methods for the preparation thereof

Country Status (23)

Country Link
US (5) US20030180222A1 (fr)
EP (1) EP1420681B1 (fr)
JP (2) JP4298501B2 (fr)
KR (2) KR20040020074A (fr)
CN (1) CN1599577A (fr)
AR (1) AR036196A1 (fr)
AU (1) AU2002318931B2 (fr)
BR (1) BR0211623A (fr)
CA (1) CA2455638C (fr)
CO (1) CO5560528A2 (fr)
EA (1) EA006239B1 (fr)
EC (1) ECSP044996A (fr)
HU (1) HUP0402029A3 (fr)
IL (1) IL160001A0 (fr)
MX (1) MXPA04000967A (fr)
NO (1) NO20040402L (fr)
NZ (1) NZ531338A (fr)
PL (1) PL368807A1 (fr)
TW (2) TWI284539B (fr)
UA (2) UA81226C2 (fr)
WO (1) WO2003011115A2 (fr)
YU (1) YU9404A (fr)
ZA (1) ZA200401606B (fr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI284539B (en) * 2001-07-30 2007-08-01 Epix Pharm Inc A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide
AU2002353823A1 (en) * 2001-10-16 2003-04-28 Epix Medical, Inc. Detection and treatment of intravascular lesions
AR047692A1 (es) * 2003-07-10 2006-02-08 Epix Medical Inc Imagenes de blancos estacionarios
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
CA2445420A1 (fr) 2003-07-29 2005-01-29 Invitrogen Corporation Tests de kinase et de phosphatase
DE102004038134B4 (de) 2004-08-05 2013-07-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Multivalente Chelatoren zum Modifizieren und Organisieren von Zielmolekülen, Verfahren zu ihrer Herstellung sowie ihre Verwendung
JP2008508333A (ja) * 2004-08-05 2008-03-21 ヨハン ウォルフガング ゲーテ−ウニベルジテート フランクフルト アム マイン 標的分子の改変および組織化のための多価キレーター
US20060275217A1 (en) * 2005-05-06 2006-12-07 Caravan Peter D Chemical exchange saturation transfer contrast agents
JP4559922B2 (ja) * 2005-06-21 2010-10-13 株式会社東芝 蛍光性錯体及びそれを用いた照明装置
US9339559B2 (en) * 2005-09-09 2016-05-17 Georgia State University Research Foundation, Inc. Targeted contrast agents and methods for targeting contrast agents
CA2614486C (fr) * 2005-07-13 2014-09-16 Georgia State University Research Foundation, Inc. Agent de contraste comportant une proteine de support et un site chelatant d'ions metalliques integre a celui-ci
KR100703593B1 (ko) * 2005-08-08 2007-04-06 경북대학교 산학협력단 Ｄｔｐａ-비스（피콜린아미드）리간드，이를 포함하는가돌리늄 착물 및 이들의 제조 방법
WO2007030802A2 (fr) * 2005-09-09 2007-03-15 Georgia State University Research Foundation, Inc. Agents de contraste cibles et leurs procedes de ciblage
CA2625196C (fr) 2005-10-07 2016-04-05 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
EP1933884B1 (fr) * 2005-10-11 2017-09-06 Huntington Medical Research Institutes Agents d'imagerie et leurs procédés d'utilisation
EP2221385A3 (fr) 2005-10-28 2010-12-01 Life Technologies Corporation Dosages de l'activité déubiquitination
FI20055653A7 (fi) 2005-12-08 2007-06-09 Wallac Oy Leimausreagenssi
WO2007073792A1 (fr) * 2005-12-19 2007-07-05 Bayer Schering Pharma Aktiengesellschaft Procede de fabrication de 4,4-diphenylcyclohexanol
US8034898B2 (en) * 2005-12-29 2011-10-11 Collagen Medical, LLC Methods of collagen imaging
EP2054514A4 (fr) 2006-08-04 2009-11-04 Univ Georgia State Res Found Capteurs d'enzyme, procédés de préparation et utilisation de tels capteurs, et procédés de détection de l'activité protéase
EP2097507B1 (fr) * 2006-12-14 2015-05-06 Georgia State University Research Foundation, Inc. Capteurs analyte et leur utilisation pour détecter l'activité d'un analyte
US9814672B2 (en) * 2007-03-09 2017-11-14 Susan T. Laing Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi
FR2914303A1 (fr) 2007-03-28 2008-10-03 Guerbet Sa Composes pour le diagnostic de l'apoptose.
FR2914304B1 (fr) 2007-03-28 2012-11-16 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de vcam.
EP2240206B1 (fr) 2008-01-08 2017-03-22 Lantheus Medical Imaging, Inc. Conjugués de n-alcoxyamide en tant qu'agents d'imagerie
US20090208421A1 (en) 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
US20090236541A1 (en) * 2008-03-24 2009-09-24 General Electric Company System and Methods for Optical Imaging
WO2009146099A2 (fr) 2008-04-02 2009-12-03 Georgia State University Research Foundation, Inc. Agents de contraste, procédés de préparation d’agents de contraste, et procédés d’imagerie
CA2732973A1 (fr) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Analogues de polypeptide insulinotrope glucose-dependant
EP2769986A3 (fr) * 2008-08-07 2014-11-26 Ipsen Pharma S.A.S. Analogues de polypeptide insulinotrope glucose-dependant (GIP) modifies a l'extremite N-terminale
JP2011530508A (ja) 2008-08-07 2011-12-22 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ グルコース依存性インスリン分泌刺激ポリペプチドのアナログ
CN104031140B (zh) * 2008-08-07 2017-04-12 益普生制药股份有限公司 糖依赖性胰岛素释放肽的截短类似物
US8889635B2 (en) 2008-09-30 2014-11-18 The Regents Of The University Of Michigan Dendrimer conjugates
WO2010054321A2 (fr) 2008-11-07 2010-05-14 The Regents Of The University Of Michigan Méthodes de traitement de troubles auto-immuns et/ou de troubles inflammatoires
US8864821B2 (en) 2008-11-26 2014-10-21 Visen Medical, Inc. Methods and compositions for identifying subjects at risk of developing stent thrombosis
FR2942227B1 (fr) 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
BRPI1009900A2 (pt) 2009-03-19 2016-03-15 Wyeth Llc métodos para a preparação de ácido [2-(8,9-dioxo-2,6-diazabiciclo[5.2.0]non-1(7)-en-2-il)etil]fosfônico e seus precursores
WO2010121133A2 (fr) 2009-04-17 2010-10-21 The General Hospital Corporation Imagerie multimodale de fibrine
WO2011005322A2 (fr) 2009-07-08 2011-01-13 Lantheus Medical Imaging, Inc. Conjugués n-alkoxyamides en tant qu'agents d'imagerie
WO2011005609A2 (fr) * 2009-07-08 2011-01-13 Mayo Foundation For Medical Education And Research Imagerie des volumes et de la motilité gastro-intestinaux
EP2488172A4 (fr) 2009-10-13 2014-08-13 Univ Michigan Compositions de dendrimères et procédés de synthèse
WO2011059586A2 (fr) 2009-10-30 2011-05-19 The Regents Of The University Of Michigan Petites molécules multifonctionnelles
EP2576502B1 (fr) * 2010-06-01 2020-08-05 Cytiva BioProcess R&D AB Nouveau chélateur et son utilisation
FR2968562B1 (fr) 2010-12-14 2013-01-11 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de muc5ac
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
US9011816B2 (en) * 2011-03-25 2015-04-21 Case Western Reserve University Fibronectin targeting contrast agent
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
US9402911B2 (en) 2011-12-08 2016-08-02 The Regents Of The University Of Michigan Multifunctional small molecules
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
US9849201B2 (en) 2013-05-03 2017-12-26 Washington University Homing agents
US10231993B2 (en) 2013-06-27 2019-03-19 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
EP3027228B1 (fr) 2013-08-01 2024-10-02 Rochester Institute of Technology Agents modulaires d'imagerie contenant des acides aminés et des peptides
US10471163B2 (en) 2013-09-13 2019-11-12 The General Hospital Corporation Activatable fibrin-binding probes
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
WO2015196208A2 (fr) 2014-06-20 2015-12-23 The General Hospital Corporation Sondes d'imagerie ciblées sur le collagène
WO2016179529A2 (fr) * 2015-05-06 2016-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Agents théarapeutiques et agents d'imagerie compagnons ciblant le mc1r
EP3101012A1 (fr) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft Nouveaux composés de chélate de gadolinium pour une utilisation dans l'imagerie par résonance magnétique
US10301358B2 (en) 2015-06-29 2019-05-28 Collagen Medical, LLC Collagen imaging compositions
US10835623B2 (en) 2015-08-13 2020-11-17 The General Hospital Corporation Manganese-based chelate conjugates for molecular MR imaging
JP7034160B2 (ja) 2016-11-28 2022-03-11 バイエル・ファルマ・アクティエンゲゼルシャフト 磁気共鳴画像法に使用するための高緩和度ガドリニウムキレート化合物
CN106946926A (zh) * 2017-02-27 2017-07-14 西北大学 一种具有多齿氨羧类二聚体螯合剂及其制备方法、应用和分离介质
CN117603148A (zh) 2017-05-05 2024-02-27 探针技术开发及商业化中心 双官能螯合物的药代动力学增强及其用途
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
EP3638320A4 (fr) 2017-05-05 2021-01-20 Centre for Probe Development and Commercialization Anticorps monoclonaux anti-igf-1r et utilisations de ceux-ci
RU2681318C1 (ru) * 2017-11-24 2019-03-06 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ получения иммуносупрессорного пептида Abu-TGIRIS-Abu, меченного ионом Gd3+
WO2020007822A1 (fr) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Nanoparticules de bismuth métallique (0), procédé de fabrication et utilisations de celles-ci
CN113164628A (zh) 2018-11-23 2021-07-23 拜耳股份有限公司 造影介质制剂及其制备方法
US20240115744A1 (en) * 2019-10-23 2024-04-11 Peter Caravan Fibrin-binding compounds for imaging and treatment
CN111233714B (zh) * 2020-03-18 2022-04-08 滨海吉尔多肽有限公司 一种maps多肽的制备方法
EP4364732A3 (fr) * 2020-07-29 2025-02-19 Universidade de Santiago de Compostela Isonitriles et produits fonctionnalisés, leur préparation et leurs utilisations

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4622420A (en) * 1980-03-18 1986-11-11 The Regents Of The University Of California Chelating agents and method
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4659839A (en) * 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4897255A (en) * 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US4880008A (en) * 1985-05-08 1989-11-14 The General Hospital Corporation Vivo enhancement of NMR relaxivity
US4678667A (en) * 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
US5099069A (en) * 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5246692A (en) * 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5001230A (en) 1988-02-18 1991-03-19 Schering Corporation T cell activation markers
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB9111199D0 (en) 1991-05-23 1991-07-17 Sandoz Ltd Improvements in or relating to organic compounds
US5364613A (en) * 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5641878A (en) 1991-05-15 1997-06-24 Diatron Corporation Porphyrin, azaporphyrin, and related fluorescent dyes free of aggregation and serum binding
US5009069A (en) * 1990-08-24 1991-04-23 Molini Alberto E Method of recovering energy from ocean water
EP0574530A4 (en) * 1991-03-08 1996-04-03 Res Corp Technologies Inc Endothelin antagonists
AU683015B2 (en) 1992-03-13 1997-10-30 Diatech, Inc. Technetium-99m labeled peptides for imaging inflammation
US5637759A (en) * 1992-07-30 1997-06-10 The Regents Of The University Of California Metal-ligating amino acid derivatives for MRI and for peptide synthesis
DE69526203T2 (de) * 1994-01-12 2002-11-28 Amersham Plc, Little Chalfont Biologische zielgerichtete mittel
US6001809A (en) * 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
DE69530392D1 (de) 1994-07-11 2003-05-22 Athena Neurosciences Inc Inhibitoren der leukozytenadhäsion
TW319763B (fr) 1995-02-01 1997-11-11 Epix Medical Inc
GB9502065D0 (en) 1995-02-02 1995-03-22 Nycomed Imaging As Contrast media
AU5752696A (en) 1995-05-18 1996-11-29 Regents Of The University Of Michigan, The Dna binding antibodies
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
DE19539409C2 (de) 1995-10-11 1999-02-18 Diagnostikforschung Inst Kontrastmittel für die Nahinfrarot-Diagnostik
CA2232245C (fr) 1995-10-17 2011-06-07 Rohm Enzyme Finland Oy Cellulases, genes les codant et utilisation de ces cellulases
DE122005000026I1 (de) 1997-04-07 2005-08-04 Genentech Inc Anti-VEGF Antik¦rper.
IT1291623B1 (it) * 1997-04-18 1999-01-11 Bracco Spa Procedimento per la coniugazione di chelanti con molecole contenenti gruppi amminici
US6342598B1 (en) * 1998-11-26 2002-01-29 Bracco International B.V. Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents
US6207858B1 (en) * 1999-03-03 2001-03-27 Idec Pharmaceuticals Corporation Regioselective synthesis of DTPA derivatives
EP1203026A4 (fr) * 1999-07-29 2005-03-16 Dyax Corp Fractions se liant la fibrine
AU6386000A (en) 1999-07-29 2001-02-19 Epix Pharmaceuticals, Inc. Targeting multimeric imaging agents through multilocus binding
AU780730B2 (en) 1999-10-01 2005-04-14 Angstrom Pharmaceuticals, Inc. Diagnostic probes and therapeutics targeting uPA and uPAR
AU2119101A (en) 1999-10-22 2001-05-08 Insight Neuroimaging Systems, Llc Ligand chelated paramagnetic mri contrast agents
AU2001231090A1 (en) * 2000-01-22 2001-07-31 Epix Medical, Inc. Magnetic resonance imaging using contrast agents bioactivated by enzymatic cleavage
US6656448B1 (en) * 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US6517814B2 (en) * 2001-01-09 2003-02-11 Bristol-Myers Squibb Pharma Company Macrocyclic chelants useful for metallopharmaceuticals
TWI284539B (en) * 2001-07-30 2007-08-01 Epix Pharm Inc A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide

Also Published As

Publication number Publication date
MXPA04000967A (es) 2005-02-17
TWI240632B (en) 2005-10-01
US20060039861A1 (en) 2006-02-23
EA006239B1 (ru) 2005-10-27
TWI284539B (en) 2007-08-01
EP1420681A4 (fr) 2009-08-05
TW200512006A (en) 2005-04-01
HUP0402029A3 (en) 2010-01-28
HUP0402029A2 (hu) 2005-01-28
US7927581B2 (en) 2011-04-19
CN1599577A (zh) 2005-03-23
JP2005314438A (ja) 2005-11-10
CA2455638C (fr) 2013-01-22
US20030180222A1 (en) 2003-09-25
CO5560528A2 (es) 2005-09-30
ECSP044996A (es) 2004-06-28
AR036196A1 (es) 2004-08-18
PL368807A1 (en) 2005-04-04
EP1420681A2 (fr) 2004-05-26
US20050074411A1 (en) 2005-04-07
KR20080100856A (ko) 2008-11-19
WO2003011115A2 (fr) 2003-02-13
JP4298501B2 (ja) 2009-07-22
CA2455638A1 (fr) 2003-02-13
AU2002318931B2 (en) 2008-01-17
NO20040402L (no) 2004-03-25
EP1420681B1 (fr) 2013-12-25
US7238341B2 (en) 2007-07-03
UA81226C2 (en) 2007-12-25
US20030216320A1 (en) 2003-11-20
WO2003011115A3 (fr) 2003-05-22
US20070185311A1 (en) 2007-08-09
US6991775B2 (en) 2006-01-31
YU9404A (sh) 2006-08-17
UA84432C2 (ru) 2008-10-27
ZA200401606B (en) 2005-05-03
EA200400241A1 (ru) 2004-06-24
BR0211623A (pt) 2004-07-13
NZ531338A (en) 2005-08-26
JP2004536875A (ja) 2004-12-09
KR20040020074A (ko) 2004-03-06

Similar Documents

Publication Publication Date Title
IL160001A0 (en) Peptide based multimeric targeted contrast agents and methods for the preparation thereof
EP1636334A4 (fr) Anticorps anti-cd30 de recombinaison et leurs utilisations
GB0130228D0 (en) Protein
EP1365022A4 (fr) Proteine associee a l'adiponectine
EP1414848A4 (fr) Les peptides "replikines" et leurs utilisations
IL157845A0 (en) Anti-epileptogenic agents
GB0108079D0 (en) Protein
EP1419175A4 (fr) Peptides de replikine et leur utilisation
GB0130720D0 (en) Proteins
GB0102447D0 (en) Protein variants and uses thereof
GB0125093D0 (en) Multimeric proteins
EP1373306A4 (fr) Proteines associees au cytoskeleton
GB0106318D0 (en) Protein
GB0130721D0 (en) Protein
SG10201403662QA (en) Replikin peptides and uses thereof
GB0130560D0 (en) Proteins
AU2002326909A8 (en) Neurotransmission-associated proteins
HK1061634A (en) Peptide-based multimeric targeted contrast agents
GB0127019D0 (en) Protein
GB0119447D0 (en) Protein
GB0124637D0 (en) Protein
GB0125717D0 (en) Protein
GB0122813D0 (en) Protein
GB0130740D0 (en) Protein
GB0114643D0 (en) Protein